Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells

Molecular Cancer Therapeutics

Volumn 1, Issue 3, 2002, Pages 185-195

  Dvorakova, Katerina ^a   Payne, Claire M ^b   Tome, Margaret E ^c   Briehl, Margaret M ^c   Vasquez, Miguel A ^a   Waltmire, Caroline N ^a   Coon, Amy ^a   Dorr, Robert T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IMINO 1,3 DIAZABICYCLO(3.1.0)HEXAN 2 ONE; 4-IMINO-1,3-DIAZABICYCLO(3.1.0)HEXAN-2-ONE; ALKANONE; CYTOCHROME C; DNA; GLUTATHIONE; MEMBRANE PROTEIN; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN 2; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL MEMBRANE POTENTIAL; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; HUMAN; IC 50; METABOLISM; MITOCHONDRION; MULTIPLE MYELOMA; OXIDATIVE STRESS; PATHOLOGY; POLYMERASE CHAIN REACTION; SECRETION; ULTRASTRUCTURE;

APOPTOSIS; CYTOCHROME C GROUP; DNA; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GLUTATHIONE; HEXANONES; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MITOCHONDRIA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; THIOREDOXIN; TUMOR CELLS, CULTURED;

EID: 0036052593     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Dvorakova, K., Payne, C. M., Tome, M. E., Briehl, M. M., McClure, T., and Dorr, R. T. Induction of oxidative stress and apoptosis in myelomacells by the aziridine-containing agent imexon. Biochem. Pharmacol., 60: 749-758, 2000. (Pubitemid 30621659)
2. Salmon, S. E., and Hersh, E. M. Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J. Natl. Cancer Inst. (Bethesda), 86: 228-230, 1994. (Pubitemid 24042265)
3. Micksche, M., Colot, M., Uchida, A., Kokoschka, E. M., Luger, T. A., Dittrich, C., Moser, K., Rainer, H., Lenzhofer, R., Kolb, R., Jakesz, R., Schempeir, M., Kokron, O., Zwick, H., Scheiner, A., Flicker, H., and Sagaster, P. Immunomodulation in cancer patients by synthetic biological response modifiers. Cancer Treatment Symposia, 1: 27-35, 1985. (Pubitemid 15149724)
4. Dorr, R. T., Liddil, J. D., Klein, M. K., and Hersh, E. M. Preclinical pharmacokinetics and antitumor activity of imexon. Investig. New Drugs, 13: 113-116, 1995.
5. Bicker, U. F. BM06 002: a new immunostimulating compound. In: M. A. Chirigos (ed.), Immune Modulation and Control of Neoplasia by Adjuvant Therapy, pp. 389-401. New York: Raven Press, 1978.
6. Hersh, E. M., Gschwind, C. R., Taylor, C. W., Dorr, R. T., Taetle, R., and Salmon, S. E. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J. Natl. Cancer Inst. (Bethesda), 84: 1238-1244, 1992.
7. Sagaster, P., Kokoschka, E. M., Kokron, O., and Micksche, M. Antitumor activity of imexon. J. Natl. Cancer Inst. (Bethesda), 87: 935-936, 1995.
8. Micksche, M., Kokoschka, E. M., Sagaster, P., and Bicker, U. Phase I study for a new immunomodulating drug, BM 06 002, in man. In: M. A. Chirigos (ed.), Immune Modulation and Control of Neoplasia by Adjuvant Therapy, pp. 403-413. New York: Raven Press, 1978.
9. Dvorakova, K., Waltmire, C. N., Payne, C. M., Tome, M. E., Briehl, M. M., and Dorr, R. T. Induction of mitochondrial changes in myeloma cells by imexon. Blood, 97: 3544-3551, 2001.
10. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983. (Pubitemid 14203433)
11. Fariss, M. W., and Reed, D. J. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol., 143: 101-109, 1987.
12. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid [published erratum appears in Anal. Biochem., 163: 279, 1987]. Anal. Biochem., 150: 76-85, 1985. (Pubitemid 16258399)
13. Rothe, G., and Valet, G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′- dichlorofluorescin. J. Leukocyte Biol., 47: 440-448, 1990. (Pubitemid 20155877)
14. L regulates the membrane potentialand volume homeostasis of mitochondria. Cell, 91: 627-637, 1997.
15. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53: 1475-1479, 1993.
16. List, A. F., Spier, C. M., Cline, A., Doll, D. C., Garewal, H., Morgan, R., and Sandberg, A. A. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br. J. Haematol., 78: 28-34, 1991.
17. Grogan, T., Dalton, W., Rybski, J., Spier, C., Meltzer, P., Richter, L., Gleason, M., Pindur, J., Cline, A., Scheper, R., et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab. Investig., 63: 815-824, 1990.
18. Huang, Y. W., Hamilton, A., Arnuk, O. J., Chaftari, P., and Chemaly, R. Current drug therapy for multiple myeloma. Drugs, 57: 485-506, 1999. (Pubitemid 29196917)
19. Joshua, D. E., MacCallum, S., and Gibson, J. Role of α interferon inmultiple myeloma. Blood Rev., 11: 191-200, 1997.
20. Shustik, C. Interferon in the treatment of multiple myeloma. Cancer Control, 5: 226-234, 1998. (Pubitemid 28280331)
21. Powis, G., Mustacich, D., and Coon, A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med., 29: 312-322, 2000.
22. Dalton, W. S. Detection of multidrug resistance gene expression in multiple myeloma. Leukemia (Baltimore), 11: 1166-1169, 1997. (Pubitemid 27345972)
23. Jonsson, B., Nilsson, K., Nygren, P., and Larsson, R. SDZ PSC-833: a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs, 3: 641-646, 1992. (Pubitemid 23028305)
24. Felts, S. J., Owen, B. A., Nguyen, P., Trepel, J., Donner, D. B., and Toft, D. O. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem., 275: 3305- 3312, 2000.
25. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science (Wash. DC), 288: 1053-1058, 2000. (Pubitemid 30324238)
26. Kickhoefer, V. A., Rajavel, K. S., Scheffer, G. L., Dalton, W. S., Scheper, R. J., and Rome, L. H. Vaults are up-regulated in multidrug-resistant cancer cell lines. J. Biol. Chem., 273: 8971-8974, 1998. (Pubitemid 28176182)
27. Costantini, P., Colonna, R., and Bernardi, P. Induction of the mitochondrial permeability transition by N-ethylmaleimide depends on secondary oxidation of critical thiol groups. Potentiation by copper-ortho-phenanthroline without dimerization of the adenine nucleotide translocase. Biochim. Biophys. Acta, 1365: 385-392, 1998. (Pubitemid 29012396)
28. Wang, T. S., Kuo, C. F., Jan, K. Y., and Huang, H. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactiveoxygen species. J. Cell. Physiol., 169: 256-268, 1996. (Pubitemid 26389031)
29. Zhu, X. H., Shen, Y. L., Jing, Y. K., Cai, X., Jia, P. M., Huang, Y., Tang, W., Shi, G. Y., Sun, Y. P., Dai, J., Wang, Z. Y., Chen, S. J., Zhang, T. D., Waxman, S., Chen, Z., and Chen, G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst., 91: 772-778, 1999. (Pubitemid 29239056)
30. Zheng, J., Deng, Y. P., Lin, C., Fu, M., Xiao, P. G., and Wu, M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int. J. Cancer, 82: 286-292, 1999. (Pubitemid 29293790)
31. Perkins, C., Kim, C. N., Fang, G., and Bhalla, K. N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood, 95: 1014-1022, 2000. (Pubitemid 30062726)
32. Ochi, T., Kaise, T., and Oya-Ohta, Y. Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia (Basel), 50: 115-120, 1994. (Pubitemid 24086624)
33. Akao, Y., Nakagawa, Y., and Akiyama, K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett., 455: 59-62, 1999. (Pubitemid 29322782)
34. Larochette, N., Decaudin, D., Jacotot, E., Brenner, C., Marzo, I., Susin, S. A., Zamzami, N., Xie, Z., Reed, J., and Kroemer, G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp. Cell Res., 249: 413-421, 1999. (Pubitemid 29397949)
35. Kroemer, G., and de The, H. Arsenic trioxide, a novel mitochondrio-toxic anticancer agent? J. Natl. Cancer Inst. (Bethesda), 91: 743-745, 1999. (Pubitemid 29239052)
36. Dai, J., Weinberg, R. S., Waxman, S., and Jing, Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood, 93: 268-277, 1999. (Pubitemid 29019412)
37. Huang, S., Huang, C. F., and Lee, T. Induction of mitosis-mediated apoptosis by sodium arsenite in HeLa S3 cells. Biochem. Pharmacol., 60: 771-780, 2000. (Pubitemid 30621661)
38. 2+M phase by sodium arsenite at lower doses. Eur. J. Haematol., 61: 27-35, 1998.
39. Li, Y. M., and Broome, J. D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res., 59: 776-780, 1999. (Pubitemid 29086725)
40. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89: 3354-3360, 1997.
41. Soignet, S. L., Maslak, P., Wang, Z. G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998. (Pubitemid 28509343)
42. Rousselot, P., Labaume, S., Marolleau, J. P., Larghero, J., Noguera, M. H., Brouet, J. C., and Fermand, J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res., 59: 1041-1048, 1999. (Pubitemid 29135964)
43. 3 exerts dose-dependent dual effects on APL cells. Blood, 89: 3345-3353, 1997.
44. Pestka, S. Identification of functional type I and type II interferon receptors. Hokkaido J. Med. Sci., 69: 1301-1319, 1994.
45. Pestka, S. The human interferon-α species and hybrid proteins. Semin Oncol., 24: S9-4-S9-17, 1997.
46. Voehringer, D. W. BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic. Biol. Med., 27: 945-950, 1999. (Pubitemid 29507468)
47. Powis, G., Kirkpatrick, D. L., Angulo, M., and Baker, A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem. Biol. Interact., 111-112: 23-34, 1998. (Pubitemid 28271931)
48. Baker, A., Payne, C. M., Briehl, M. M., and Powis, G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res., 57: 5162-5167, 1997. (Pubitemid 27498136)
49. Powis, G., Briehl, M., and Oblong, J. Redox signalling and the control of cell growth and death. Pharmacol. Ther., 68: 149-173, 1995.
50. Spyrou, G., Enmark, E., Miranda-Vizuete, A., and Gustafsson, J. Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem., 272: 2936-2941, 1997. (Pubitemid 27053344)
51. Nomura, K., Imai, H., Koumura, T., Kobayashi, T., and Nakagawa, Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. Biochem. J., 351: 183-193, 2000.
52. Arch, R. H., and Thompson, C. B. Lymphocyte survival: the struggle against death. Annu. Rev. Cell Dev. Biol., 15: 113-140, 1999. (Pubitemid 32250373)
53. Borg, A. G., Burgess, R., Green, L. M., Scheper, R. J., and Yin, J. A. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br. J. Haematol., 103: 1083-1091, 1998. (Pubitemid 29012648)